InvestorsHub Logo
Followers 58
Posts 10142
Boards Moderated 1
Alias Born 09/21/2016

Re: sokol post# 166453

Saturday, 09/22/2018 1:59:21 PM

Saturday, September 22, 2018 1:59:21 PM

Post# of 462171

Ariana is coming right out with and stating ”efficacy”, ”actionable genetic variant biomakrers”, identification of patients that benefit from AVXL 2-73 and go on to say ”a confirmed response with ANAVEX 2-73”. These are strong and confident words.

”Ariana Pharma helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase IIa clinical trial.

Ariana’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73.”




May we read that as...practitioners of precision medicine now have evidence that some AD is treatable?

Danke.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News